Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
Bonello F, Rocchi S, Barilà G, Sandrone M, Talarico M, Zamagni E, Scaldaferri M, Vedovato S, Bertiond C, Pavan L, Bringhen S, Cattel F, Zambello R, Cavo M, Mina R. Bonello F, et al. Among authors: rocchi s. Front Oncol. 2022 Mar 14;12:851864. doi: 10.3389/fonc.2022.851864. eCollection 2022. Front Oncol. 2022. PMID: 35359355 Free PMC article.
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma.
Zamagni E, Nanni C, Tacchetti P, Pantani L, Marzocchi G, Zannetti B, Terragna C, Mancuso K, Rocchi S, Pezzi A, Testoni N, Fanti S, Cavo M. Zamagni E, et al. Among authors: rocchi s. Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):e101-4. doi: 10.1016/j.clml.2013.12.014. Epub 2013 Dec 26. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24508412 No abstract available.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M. Tacchetti P, et al. Among authors: rocchi s. Am J Hematol. 2014 Dec;89(12):1085-91. doi: 10.1002/ajh.23835. Epub 2014 Sep 17. Am J Hematol. 2014. PMID: 25159313 Free article. Clinical Trial.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M. Zannetti BA, et al. Among authors: rocchi s. Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035. Am J Hematol. 2015. PMID: 25858483 Free article.
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M. Zamagni E, et al. Among authors: rocchi s. Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15. Clin Cancer Res. 2015. PMID: 26078390
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bellò M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauviè S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M. Zamagni E, et al. Among authors: rocchi s. Leukemia. 2016 Feb;30(2):417-22. doi: 10.1038/leu.2015.291. Epub 2015 Oct 22. Leukemia. 2016. PMID: 26490489
231 results